Chemed’s Resilience Amid Challenges: Justifying a Buy Rating with Strong Long-Term Prospects

Analyst Joanna Gajuk of Bank of America Securities reiterated a Buy rating on Chemed (CHE – Research Report), reducing the price target to $650.00.

Joanna Gajuk’s rating is based on several key considerations despite some challenges facing Chemed. The company has encountered issues such as a Medicare cap headwind and weaker residential performance from Roto-Rooter. However, these are not unexpected, and adjustments have been made to account for these factors, including a reduction in future earnings estimates. Despite these short-term pressures, the long-term outlook remains positive due to Chemed’s strong fundamentals.
Chemed’s ability to grow in new markets and adjust its admission mix over time is expected to mitigate the impact of the Medicare cap. Additionally, the company maintains a clean balance sheet and robust cash flows, which are attractive to investors. Furthermore, the hospice segment is not exposed to potential spending cuts, providing additional stability. These factors contribute to the confidence in Chemed’s longer-term growth prospects, justifying the Buy rating with a price objective of $650.

Gajuk covers the Healthcare sector, focusing on stocks such as UnitedHealth, Chemed, and HCA Healthcare. According to TipRanks, Gajuk has an average return of -0.1% and a 56.99% success rate on recommended stocks.